Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome

BMC Medical Genetics

Volumn 11, Issue 1, 2010, Pages

  Ma, Wanlong ^a   Kantarjian, Hagop ^b   Zhang, Ke ^a   Zhang, Xi ^a   Wang, Xiuqiang ^a   Chen, Clifford ^a   Donahue, Amber C ^a   Zhang, Zhong ^a   Yeh, Chen Hsiung ^a   O'Brien, Susan ^b   Garcia Manero, Guillermo ^b   Caporaso, Neil ^c   Landgren, Ola ^c   Albitar, Maher ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROL GROUP; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; OVERALL SURVIVAL; PROMOTER REGION; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; ERYTHROPOIETIN; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROMOTER REGIONS, GENETIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78149493949     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-11-163     Document Type: Article

References (18)

1. Kasner MT, Luger SM. Update on the therapy for myelodysplastic syndrome. Am J Hematol 1997, 84(3):177-186.
2. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol 2008, 35(4):418-429. 10.1053/j.seminoncol.2008.04.012, 2600445, 18692692.
3. Descatha A, Jenabian A, Conso F, Ameille J. Occupational exposures and haematological malignancies: overview on human recent data. Cancer Causes Control 2005, 16(8):939-953. 10.1007/s10552-005-2301-3, 16132803.
4. Powers MP, Nishino H, Luo Y, Raza A, Vanguri A, Rice L, Zu Y, Chang CC. Polymorphisms in TGFbeta and TNFalpha are associated with the myelodysplastic syndrome phenotype. Arch Pathol Lab Med 2007, 131(12):1789-1793.
5. Gyulai Z, Balog A, Borbényi Z, Mándi Y. Genetic polymorphisms in patients with myelodysplastic syndrome. Acta Microbiol Immunol Hung 2005, 52(3-4):463-475. 10.1556/AMicr.52.2005.3-4.15, 16400883.
6. Broberg K, Huynh E, Schläwicke E, Björk J, Albin M, Ingvar C, Olssön H, Höglund M. Association between polymorphisms in RMI1, TOP3A, and BLM and risk of cancer, a case-control study. BMC Cancer 2009, 9:140. 10.1186/1471-2407-9-140, 2685436, 19432957.
7. Tong Z, Yang Z, Patel S, Chen H, Gibbs D, Yang X, Hau VS, Kaminoh Y, Harmon J, Pearson E, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008, 105(19):6998-7003. 10.1073/pnas.0800454105, 2383970, 18458324.
8. Metcalf D. Hematopoietic cytokines. Blood 2008, 111(2):485-491. 10.1182/blood-2007-03-079681, 2200848, 18182579.
9. Fried W. Erythropoietin and erythropoiesis. Exp Hematol 2009, 37(9):1007-1015. 10.1016/j.exphem.2009.05.010, 19500646.
10. Wadhwa M, Thorpe R. Haematopoietic growth factors and their therapeutic use. Throm Haemost 2008, 99(5):863-873.
11. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005, 15(3):146-155. 10.1016/j.tcb.2005.01.007, 15752978.
12. Negrin RS, Stein R, Vardiman J, Doherty K, Cornwell J, Krantz S, Greenberg PL. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993, 82(3):737-743.
13. Negrin RS, Stein R, Doherty K, Cornwell J, Vardiman J, Krantz S, Greenberg PL. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996, 87(10):4076-4081.
14. Stein RS. The role of erythropoietin in the anemia of myelodysplastic syndrome. Clin Lymphoma 2003, 4(Suppl 1):S36-40. 10.3816/CLM.2003.s.007, 14556674.
15. Jädersten M, Malcovati L, Dybedal I, Della Porta MG, Invernizzi R, Montgomery SM, Pascutto C, Porwit A, Cazzola M, Hellström-Lindberg E. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26(21):3607-13. 10.1200/JCO.2007.15.4906, 18559873.
16. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, Coiteux V, Leroux G, Lepelley P, Daniel MT, Cheze S, Mahé B, Ferrant A, Ravoet C, Escoffre-Barbe M, Adès L, Vey N, Aljassem L, Stamatoullas A, Mannone L, Dombret H, Bourgeois K, Greenberg P, Fenaux P, Dreyfus F, . GFM group (Groupe Francophone des Myélodysplasies) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111(2):574-82. 10.1182/blood-2007-06-096370, 17940203, GFM group (Groupe Francophone des Myélodysplasies).
17. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, Paietta E, van der Jagt R, Houston J, Thomas ML, Cella D, Rowe JM. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009, 114(12):2393-400. 10.1182/blood-2009-03-211797, 2746469, 19564636.
18. Valent P. Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. Leuk Res 2008, 32(9):1333-7. 10.1016/j.leukres.2008.02.022, 18417212.